Valuation: Xencor, Inc.

Market Cap 2.55B 2.33B 2.15B 1.95B 3.65B 238B 3.82B 26.02B 10.32B 129B 9.57B 9.37B 408B P/E 2026 *
-14.8x
P/E 2027 * -9.5x
Enterprise Value 2.05B 1.87B 1.73B 1.56B 2.93B 191B 3.07B 20.9B 8.29B 103B 7.69B 7.53B 328B EV / Sales 2026 *
10.3x
EV / Sales 2027 * 22x
Free-Float
98.81%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Xencor, Inc.

1 day-1.10%
1 week-10.81%
Current month+14.05%
1 month+46.66%
3 months+23.58%
6 months+226.71%
Current year+122.14%
1 week 33.58
Extreme 33.58
37.39
1 month 24.42
Extreme 24.42
40.6
Current year 10.38
Extreme 10.375
40.6
1 year 10.38
Extreme 10.375
40.6
3 years 6.92
Extreme 6.92
40.6
5 years 6.92
Extreme 6.92
42.3
10 years 6.92
Extreme 6.92
58.34
Manager TitleAgeSince
Chief Executive Officer 55 01/02/2005
Director of Finance/CFO 48 09/04/2024
Chief Tech/Sci/R&D Officer 61 01/10/2006
Director TitleAgeSince
Director/Board Member 55 01/08/1997
Director/Board Member 58 25/07/2014
Director/Board Member 72 18/03/2015
Date Insider Type Main position Quantity % Market Cap. Importance
16/6/26 Free

Director

30,906 0.0417%
10/4/26 Sell

Chief Financial Officer

3,499 0.0048%
5/3/26 Sell

Chief Technology Officer

6,620 0.0090%
Change 5-day change 1-year change 3-year change Capi.($)
-1.10%-10.81%+115.66%+76.95% 2.55B
+0.19%-3.96%+54.92%+69.15% 65.42B
-0.68%-2.96%+6.15%+89.13% 58.91B
-1.21%-1.26%+24.08%+84.10% 55.24B
-0.97%-3.91%+12.98%+113.88% 45.66B
-2.83%-7.58%+15.21%+22.34% 41.29B
+3.61%+2.63%+21.96%+46.39% 36.82B
-0.24%-9.59%+126.05%+647.44% 34.48B
-0.33%+0.93%+77.82%+56.76% 32.5B
+20.58%+22.35%-29.03%+482.03% 31.69B
Average +1.70%-1.75%+42.58%+168.82% 40B
Weighted average by Cap. +1.26%-1.06%+33.53%+152.99%

Financials

2026 *2027 *
Net sales 199M 181M 168M 152M 284M 18.55B 297M 2.02B 803M 10.02B 745M 730M 31.75B 116M 106M 97.68M 88.36M 166M 10.82B 173M 1.18B 468M 5.85B 435M 425M 18.52B
Net income -176M -161M -149M -134M -252M -16.46B -264M -1.8B -713M -8.89B -661M -647M -28.17B -310M -283M -262M -237M -444M -28.97B -465M -3.16B -1.25B -15.65B -1.16B -1.14B -49.59B
Net Debt -502M -457M -423M -383M -718M -46.88B -752M -5.12B -2.03B -25.33B -1.88B -1.84B -80.25B -
Projected Income Statement - Annual - Xencor, Inc.
Logo Xencor, Inc.
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Employees
260
Date Price Change Volume
19/11/26 USD 34.01 -1.10% 1,091,499
18/11/26 USD 34.39 -0.32% 867,473
17/11/26 USD 34.50 -2.54% 1,616,922
16/11/26 USD 35.40 -4.56% 1,033,607
13/11/26 USD 37.09 -2.73% 958,164
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Xencor, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
34.01USD
Average target price
43.83USD
Spread / Average Target
+28.88%
  1. Stock Market
  2. Stocks
  3. XNCR Stock